15 days ago
Grab Holdings (NASDAQ:GRAB), a super-app for ride-hailing, deliveries, and digital financial services, closed at $2.87, down 1.37%. The stock moved after Grab announced a $1.49 billion cash deal for a 60% stake in Atome Financial. Investors are watching the financial services expansion and consumer lending reach looking ahead. Trading volume reached 82.1M shares, coming in about 72% above its three-month average of 47.6M shares. Grab Holdings IPO'd in 2020 and has fallen 76% since going public.
The S&P 500 (SNPINDEX:^GSPC) fell 0.43% to 7,553, and the Nasdaq Composite (NASDAQINDEX:^IXIC) slipped 0.01% to 25,978. Among ride-hailing, delivery, and consumer fintech platforms, Uber Technologies (NYSE:UBER) closed at $71.01, down 0.59%, while Lyft (NASDAQ:LYFT) finished at $15.69, unchanged, as mobility peers remained in focus.
Grab, the Southeast Asian delivery, mobility, and financial services upstart, continues to show it intends to become the leading "superapp" in its niche after acquiring 60% of Atome Financial for $1.49 billion today. Prior to the deal, Grab held over $6 billion in cash versus minimal debt, so the deal shouldn't be a funding problem by any means.
Atome Financial operates in five of Grab's six markets and brings over 25 million unique transacting users, helping to beef up the latter's fintech offerings. Atome has seen its gross merchandise volume grow ninefold over the last six years and is profitable on an adjusted EBITDA basis.
As of 2024, merely 5% of Southeast Asian adults owned a credit card and only 14% had borrowed from a financial institution, so the potential here for Grab could be massive if they execute successfully upon this opportunity.
#billion #deal #lyft
The S&P 500 (SNPINDEX:^GSPC) fell 0.43% to 7,553, and the Nasdaq Composite (NASDAQINDEX:^IXIC) slipped 0.01% to 25,978. Among ride-hailing, delivery, and consumer fintech platforms, Uber Technologies (NYSE:UBER) closed at $71.01, down 0.59%, while Lyft (NASDAQ:LYFT) finished at $15.69, unchanged, as mobility peers remained in focus.
Grab, the Southeast Asian delivery, mobility, and financial services upstart, continues to show it intends to become the leading "superapp" in its niche after acquiring 60% of Atome Financial for $1.49 billion today. Prior to the deal, Grab held over $6 billion in cash versus minimal debt, so the deal shouldn't be a funding problem by any means.
Atome Financial operates in five of Grab's six markets and brings over 25 million unique transacting users, helping to beef up the latter's fintech offerings. Atome has seen its gross merchandise volume grow ninefold over the last six years and is profitable on an adjusted EBITDA basis.
As of 2024, merely 5% of Southeast Asian adults owned a credit card and only 14% had borrowed from a financial institution, so the potential here for Grab could be massive if they execute successfully upon this opportunity.
#billion #deal #lyft
15 days ago
When planning for retirement, most people account for housing, travel, daily living expenses and general healthcare costs. However, it's easy to overlook one retirement expense: the Income-Related Monthly Adjustment Amount, commonly known as IRMAA.
If you have a large pension, substantial tax-deferred retirement accounts, or other variables that may elevate your retirement income, IRMAA is a factor you may encounter starting in your mid-60s. While it is unlikely to derail a well-constructed financial plan, failing to understand IRMAA and how to plan ahead for it can lead to frustrating annual surprises.
In the United States, most adults become eligible for Medicare when they turn 65. Medicare is divided into several parts, but IRMAA specifically applies to two of them: Part B (which covers doctor visits, outpatient care and preventive services) and Part D (prescription drug coverage).
For the average retiree, Medicare Part B carries a standard monthly base premium ($202.90 per month in 2026). Part D coverage varies depending on the specific private plan selected, but carries a national average base premium of roughly $38.99 per month. Combined, a standard retiree pays roughly $242 per month for basic Part B and Part D coverage, per Medicare.
However, Medicare premiums are not one-size-fits-all. If your income exceeds specific threshold limits set by the federal government, you will be required to pay an additional surcharge on top of your base monthly premiums. That additional surcharge is IRMAA.
#income #base
If you have a large pension, substantial tax-deferred retirement accounts, or other variables that may elevate your retirement income, IRMAA is a factor you may encounter starting in your mid-60s. While it is unlikely to derail a well-constructed financial plan, failing to understand IRMAA and how to plan ahead for it can lead to frustrating annual surprises.
In the United States, most adults become eligible for Medicare when they turn 65. Medicare is divided into several parts, but IRMAA specifically applies to two of them: Part B (which covers doctor visits, outpatient care and preventive services) and Part D (prescription drug coverage).
For the average retiree, Medicare Part B carries a standard monthly base premium ($202.90 per month in 2026). Part D coverage varies depending on the specific private plan selected, but carries a national average base premium of roughly $38.99 per month. Combined, a standard retiree pays roughly $242 per month for basic Part B and Part D coverage, per Medicare.
However, Medicare premiums are not one-size-fits-all. If your income exceeds specific threshold limits set by the federal government, you will be required to pay an additional surcharge on top of your base monthly premiums. That additional surcharge is IRMAA.
#income #base
15 days ago
Evommune, Inc. (NYSE:EVMN) announced on September 8 that EVO756 missed its primary endpoint in a randomized, double-blind, placebo-controlled Phase 2b trial involving 121 adults with moderate-to-severe atopic dermatitis. The primary measure was the percentage change from baseline in Eczema Area and Severity Index, or EASI, at week 12. No tested dose met the primary or secondary endpoints, and development in that indication will stop.
Evommune, Inc. (NYSE:EVMN) had already discontinued EVO756 for chronic spontaneous urticaria following a June trial failure. Development continues in migraine prevention. The setbacks place greater weight on EVO301, which has positive Phase 2a eczema data and a Phase 2b study planned for mid-2027.
Evommune, Inc. (NYSE:EVMN) has clinical evidence supporting its next eczema program. In February, the company reported that EVO301 met the primary endpoint in a randomized, double-blind, placebo-controlled Phase 2a trial involving 70 adults. Participants received two intravenous doses or placebo over a 12-week study.
Evommune, Inc. (NYSE:EVMN) reported a 55% EASI reduction with EVO301 versus 22% with placebo at week 12, a difference of 33 percentage points. The study met its prespecified Bayesian success criterion, and a separate conventional ****** ysis showed statistical significance at p
Evommune, Inc. (NYSE:EVMN) had already discontinued EVO756 for chronic spontaneous urticaria following a June trial failure. Development continues in migraine prevention. The setbacks place greater weight on EVO301, which has positive Phase 2a eczema data and a Phase 2b study planned for mid-2027.
Evommune, Inc. (NYSE:EVMN) has clinical evidence supporting its next eczema program. In February, the company reported that EVO301 met the primary endpoint in a randomized, double-blind, placebo-controlled Phase 2a trial involving 70 adults. Participants received two intravenous doses or placebo over a 12-week study.
Evommune, Inc. (NYSE:EVMN) reported a 55% EASI reduction with EVO301 versus 22% with placebo at week 12, a difference of 33 percentage points. The study met its prespecified Bayesian success criterion, and a separate conventional ****** ysis showed statistical significance at p
16 days ago
The Southwest faces a barrage of intense rain this week as rounds of storms are tapping into unusually moisture-rich air being pulled north from Baja California, after flash flooding in New Mexico killed three people early Wednesday.
Officers responded at around 12:30 a.m. local time to a report of three people washed away by flooding near Newcomb, New Mexico, on the Navajo Nation. Police discovered two adults and one juvenile on scene, the Navajo Police Department said in a statement. All three were ****** ounced dead. The department declined to provide further details about the deaths when contacted by CNN, citing concern for the family’s privacy.
🌧️ Get your local forecast from the CNN Weather app
Rainfall over Newcomb began Tuesday afternoon around 4:30 p.m. and lingered intermittently until just after midnight. The area saw around 0.5 inches to 1 inch of rain in total, with most of it falling within an hour Tuesday evening.
Wednesday’s storms prompted a rare Level 3 of 4 risk of flooding rainfall for parts of Arizona and New Mexico, including Phoenix and Tucson. Phoenix had not faced a flood risk that high since 2022.
#flooding #around #wednesday #navajo
Officers responded at around 12:30 a.m. local time to a report of three people washed away by flooding near Newcomb, New Mexico, on the Navajo Nation. Police discovered two adults and one juvenile on scene, the Navajo Police Department said in a statement. All three were ****** ounced dead. The department declined to provide further details about the deaths when contacted by CNN, citing concern for the family’s privacy.
🌧️ Get your local forecast from the CNN Weather app
Rainfall over Newcomb began Tuesday afternoon around 4:30 p.m. and lingered intermittently until just after midnight. The area saw around 0.5 inches to 1 inch of rain in total, with most of it falling within an hour Tuesday evening.
Wednesday’s storms prompted a rare Level 3 of 4 risk of flooding rainfall for parts of Arizona and New Mexico, including Phoenix and Tucson. Phoenix had not faced a flood risk that high since 2022.
#flooding #around #wednesday #navajo
16 days ago
In some markets, it costs less to rent than to buy — by a lot. And it could be a great way to save a ton of money during your retirement years.
Mortgage and financial consultant Cody Schuiteboer of Best Interest Financial said many retirees never even consider renting as a serious option.
"There is an unshakeable mentality that buying is always the right choice, but the opposite is often true in retirement," he said. "If renting is actually cheaper in that market, renting lets retirees stretch their nest egg further."
MoneyLion ran the rent-versus-ownership numbers in the top retirement destinations along the East Coast and found the cities offering the greatest savings to renters. The homeownership numbers ****** umed a 10% down payment and a 6.53% interest rate, using average home price and rent numbers from Zillow.
Best of all, the following retirement hubs all have a total monthly expenditure cost under $4,000 according to BLS data, and adults over 65 make up at least 20% of the population.
#rent
Mortgage and financial consultant Cody Schuiteboer of Best Interest Financial said many retirees never even consider renting as a serious option.
"There is an unshakeable mentality that buying is always the right choice, but the opposite is often true in retirement," he said. "If renting is actually cheaper in that market, renting lets retirees stretch their nest egg further."
MoneyLion ran the rent-versus-ownership numbers in the top retirement destinations along the East Coast and found the cities offering the greatest savings to renters. The homeownership numbers ****** umed a 10% down payment and a 6.53% interest rate, using average home price and rent numbers from Zillow.
Best of all, the following retirement hubs all have a total monthly expenditure cost under $4,000 according to BLS data, and adults over 65 make up at least 20% of the population.
#rent
16 days ago
GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at risk. The decision reflects declining demand for traditional egg-based flu vaccines, which has left GSK with more manufacturing capacity than it needs. GSK reviewed its Dresden and Ste-Foy, Canada, flu vaccine sites and chose to consolidate production in Canada, which it says can meet anticipated demand more sustainably and competitively.
The closure comes as GSK plc (NYSE:GSK) is shifting its influenza strategy toward newer technology: the company is advancing an mRNA-based seasonal flu vaccine into Phase III after Phase II results showed stronger immune responses than standard-dose vaccines in younger adults and high-dose vaccines in older adults. The broader vaccine environment has also weakened, with Reuters reporting declining sales across flu, RSV, and other vaccines amid lower demand and policy-related pressures, increasing the importance of manufacturing discipline and portfolio selection.
Copyright: kadmy / 123RF Stock Photo
The closure could ultimately strengthen GSK plc (NYSE:GSK)'s margins and cash generation by removing excess capacity from a declining part of the influenza market rather than continuing to carry the fixed costs of an underutilized facility. GSK explicitly said demand for traditional egg-based flu vaccines is falling and that it has more capacity than required, while the Canadian facility can meet anticipated future demand competitively.
This is particularly important because GSK's vaccine business remains a significant earnings contributor but is increasingly being driven by products with better growth prospects: second-quarter 2026 vaccine sales rose 8% to £2.3 billion, with meningitis vaccines up 21% and Arexvy sales increasing by more than 100%, while Shingrix generated £0.9 billion. The Dresden decision therefore looks less like a retreat from vaccines overall and more like a reallocation of manufacturing capacity away from mature egg-based products toward higher-value technologies.
#demand #Manufacturing
The closure comes as GSK plc (NYSE:GSK) is shifting its influenza strategy toward newer technology: the company is advancing an mRNA-based seasonal flu vaccine into Phase III after Phase II results showed stronger immune responses than standard-dose vaccines in younger adults and high-dose vaccines in older adults. The broader vaccine environment has also weakened, with Reuters reporting declining sales across flu, RSV, and other vaccines amid lower demand and policy-related pressures, increasing the importance of manufacturing discipline and portfolio selection.
Copyright: kadmy / 123RF Stock Photo
The closure could ultimately strengthen GSK plc (NYSE:GSK)'s margins and cash generation by removing excess capacity from a declining part of the influenza market rather than continuing to carry the fixed costs of an underutilized facility. GSK explicitly said demand for traditional egg-based flu vaccines is falling and that it has more capacity than required, while the Canadian facility can meet anticipated future demand competitively.
This is particularly important because GSK's vaccine business remains a significant earnings contributor but is increasingly being driven by products with better growth prospects: second-quarter 2026 vaccine sales rose 8% to £2.3 billion, with meningitis vaccines up 21% and Arexvy sales increasing by more than 100%, while Shingrix generated £0.9 billion. The Dresden decision therefore looks less like a retreat from vaccines overall and more like a reallocation of manufacturing capacity away from mature egg-based products toward higher-value technologies.
#demand #Manufacturing
16 days ago
GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at risk. The decision reflects declining demand for traditional egg-based flu vaccines, which has left GSK with more manufacturing capacity than it needs. GSK reviewed its Dresden and Ste-Foy, Canada, flu vaccine sites and chose to consolidate production in Canada, which it says can meet anticipated demand more sustainably and competitively.
The closure comes as GSK plc (NYSE:GSK) is shifting its influenza strategy toward newer technology: the company is advancing an mRNA-based seasonal flu vaccine into Phase III after Phase II results showed stronger immune responses than standard-dose vaccines in younger adults and high-dose vaccines in older adults. The broader vaccine environment has also weakened, with Reuters reporting declining sales across flu, RSV, and other vaccines amid lower demand and policy-related pressures, increasing the importance of manufacturing discipline and portfolio selection.
Copyright: kadmy / 123RF Stock Photo
The closure could ultimately strengthen GSK plc (NYSE:GSK)'s margins and cash generation by removing excess capacity from a declining part of the influenza market rather than continuing to carry the fixed costs of an underutilized facility. GSK explicitly said demand for traditional egg-based flu vaccines is falling and that it has more capacity than required, while the Canadian facility can meet anticipated future demand competitively.
This is particularly important because GSK's vaccine business remains a significant earnings contributor but is increasingly being driven by products with better growth prospects: second-quarter 2026 vaccine sales rose 8% to £2.3 billion, with meningitis vaccines up 21% and Arexvy sales increasing by more than 100%, while Shingrix generated £0.9 billion. The Dresden decision therefore looks less like a retreat from vaccines overall and more like a reallocation of manufacturing capacity away from mature egg-based products toward higher-value technologies.
#vaccine
The closure comes as GSK plc (NYSE:GSK) is shifting its influenza strategy toward newer technology: the company is advancing an mRNA-based seasonal flu vaccine into Phase III after Phase II results showed stronger immune responses than standard-dose vaccines in younger adults and high-dose vaccines in older adults. The broader vaccine environment has also weakened, with Reuters reporting declining sales across flu, RSV, and other vaccines amid lower demand and policy-related pressures, increasing the importance of manufacturing discipline and portfolio selection.
Copyright: kadmy / 123RF Stock Photo
The closure could ultimately strengthen GSK plc (NYSE:GSK)'s margins and cash generation by removing excess capacity from a declining part of the influenza market rather than continuing to carry the fixed costs of an underutilized facility. GSK explicitly said demand for traditional egg-based flu vaccines is falling and that it has more capacity than required, while the Canadian facility can meet anticipated future demand competitively.
This is particularly important because GSK's vaccine business remains a significant earnings contributor but is increasingly being driven by products with better growth prospects: second-quarter 2026 vaccine sales rose 8% to £2.3 billion, with meningitis vaccines up 21% and Arexvy sales increasing by more than 100%, while Shingrix generated £0.9 billion. The Dresden decision therefore looks less like a retreat from vaccines overall and more like a reallocation of manufacturing capacity away from mature egg-based products toward higher-value technologies.
#vaccine
16 days ago
A commonly used drug has been linked to a higher risk of death in a new study.
The antibiotic, cefepime, which is used to treat bacterial infections like pneumonia, UTIs and skin infections, is typically administered via injection by healthcare providers in a clinical setting.
Severe side effects may include confusion, decreased consciousness or seizures, especially in older patients and those with kidney problems, among many other common symptoms, according to Mayo Clinic.
Older Adults Taking 5 Or More Prescription Drugs Face Higher Risk Of Death, Study Finds
New research suggests the medication may be ****** ociated with a higher risk of all-cause mortality.
#risk
The antibiotic, cefepime, which is used to treat bacterial infections like pneumonia, UTIs and skin infections, is typically administered via injection by healthcare providers in a clinical setting.
Severe side effects may include confusion, decreased consciousness or seizures, especially in older patients and those with kidney problems, among many other common symptoms, according to Mayo Clinic.
Older Adults Taking 5 Or More Prescription Drugs Face Higher Risk Of Death, Study Finds
New research suggests the medication may be ****** ociated with a higher risk of all-cause mortality.
#risk
18 days ago
A new CDC report reveals that fatigue is a widespread concern among U.S. adults, with nearly three-quarters reporting feeling very tired or exhausted on multiple days over the past three months. Board-certified sleep specialist Dr. Carol Ash explains the causes of fatigue and shares simple tips to improve sleep and boost energy.
#widespread
#widespread
20 days ago
Long before the first serve in the US Open Women's Final on Saturday, there were different players on the iconic courts.
Children and adults with disabilities were in the spotlight at Flushing Meadows. They learned the basics of tennis and put them on display at the Court of Dreams clinic.
Fifteen-year-old Thaddeus Henry had been a participant at the US Open through the non-profit ACEing Autism for the past eight years.
"It's just a pleasure to see how far he's come," said his mother, Carla Rogers-Henry.
Rogers-henry explains why they keep coming.
#final #children
Children and adults with disabilities were in the spotlight at Flushing Meadows. They learned the basics of tennis and put them on display at the Court of Dreams clinic.
Fifteen-year-old Thaddeus Henry had been a participant at the US Open through the non-profit ACEing Autism for the past eight years.
"It's just a pleasure to see how far he's come," said his mother, Carla Rogers-Henry.
Rogers-henry explains why they keep coming.
#final #children
21 days ago
Sen. Ted Cruz (Texas), a prominent conservative voice in the Senate GOP conference, says he's willing to support President Trump's proposal to give $5,000 dividend payments to U.S. adults provided that they are structured as tax refunds and go to people who work and pay taxes.
Asked about Trump's proposal, Cruz told Fox News's Jesse Watters that his support "depends on how it's structured."
"I would like to see it structured as a tax refund," he said. "I would be all for structuring it as a tax refund."
"But I think we should be incentivizing work. I don't think we should be paying people that are not working," he argued.
Trump unveiled the proposal at the GOP midterm convention in Dallas and has drawn pushback from both Republican moderates and conservatives.
#texas
Asked about Trump's proposal, Cruz told Fox News's Jesse Watters that his support "depends on how it's structured."
"I would like to see it structured as a tax refund," he said. "I would be all for structuring it as a tax refund."
"But I think we should be incentivizing work. I don't think we should be paying people that are not working," he argued.
Trump unveiled the proposal at the GOP midterm convention in Dallas and has drawn pushback from both Republican moderates and conservatives.
#texas
21 days ago
Nyxoah SA (NASDAQ:NYXH) announced the first patient implantation in BREATHE on September 7. The prospective, single-arm U.S. post-approval study will evaluate Genio hypoglossal-nerve stimulation in adults aged 22 or older with moderate to severe obstructive sleep apnea for whom standard-care treatments have failed, cannot be tolerated, or are unsuitable. Plans call for up to 229 patients at up to 25 centers, with follow-up lasting up to five years.
For Nyxoah SA (NASDAQ:NYXH), the milestone begins a new phase of evidence collection following Genio's August 2025 FDA approval. The co-primary effectiveness endpoints are apnea-hypopnea-index and oxygen-desaturation-index responder rates at 12 months. Device- and procedure-related serious adverse events will be **** sed at 12 months and annually thereafter. The investment question is whether that evidence can help turn clinical credibility into sustained commercial adoption.
Nyxoah SA (NASDAQ:NYXH) has an opportunity to demonstrate how Genio performs across different physicians and treatment settings. Consistent outcomes across participating centers could give referring sleep physicians and implanting surgeons greater confidence in patient selection and treatment delivery.
The product offers a distinct approach. Genio stimulates hypoglossal nerves on both sides of the tongue, using a battery-free implant powered by an external wearable. For Nyxoah SA (NASDAQ:NYXH), documenting effectiveness and safety in routine practice could help physicians **** s how that design fits their patients' needs.
Longer follow-up could also strengthen the evidence available to payers. Nyxoah SA (NASDAQ:NYXH) could use sustained responses and safety findings to support coverage discussions, while participating centers gain practical experience with implantation and follow-up. That would make BREATHE valuable beyond a single headline response rate.
#nyxoah #NASDAQ #nyxh
For Nyxoah SA (NASDAQ:NYXH), the milestone begins a new phase of evidence collection following Genio's August 2025 FDA approval. The co-primary effectiveness endpoints are apnea-hypopnea-index and oxygen-desaturation-index responder rates at 12 months. Device- and procedure-related serious adverse events will be **** sed at 12 months and annually thereafter. The investment question is whether that evidence can help turn clinical credibility into sustained commercial adoption.
Nyxoah SA (NASDAQ:NYXH) has an opportunity to demonstrate how Genio performs across different physicians and treatment settings. Consistent outcomes across participating centers could give referring sleep physicians and implanting surgeons greater confidence in patient selection and treatment delivery.
The product offers a distinct approach. Genio stimulates hypoglossal nerves on both sides of the tongue, using a battery-free implant powered by an external wearable. For Nyxoah SA (NASDAQ:NYXH), documenting effectiveness and safety in routine practice could help physicians **** s how that design fits their patients' needs.
Longer follow-up could also strengthen the evidence available to payers. Nyxoah SA (NASDAQ:NYXH) could use sustained responses and safety findings to support coverage discussions, while participating centers gain practical experience with implantation and follow-up. That would make BREATHE valuable beyond a single headline response rate.
#nyxoah #NASDAQ #nyxh
21 days ago
"The Secret Lives of Mormon Wives" star Layla Taylor is finally living in her truth, and things couldn't be better. In a new interview, the reality star, who recently came out as bisexual in the summer of 2026, shared more about her life now that she's open about her ******* uality and explained why she decided now was the right time to come out.
Speaking with PEOPLE, Taylor said the main reason she came out was to encourage those who might also be struggling to accept themselves.
"The only reason why I did formally address it is just to help youth that are feeling the same way, that are scared to come out — and even adults that are the same way, that are scared to come out — was just to share my story so I could help other people," he said.
According to a previous report from The Blast, the Hulu star told podcast host Jay Shetty that she was "gay and bi" before saying her breakup with her last boyfriend inspired her to act on her attraction to women.
Elsewhere in her interview, Taylor said that she was surprised to learn people in the LGBTQ+ community still experience ******* phobia.
#people #reason #same
Speaking with PEOPLE, Taylor said the main reason she came out was to encourage those who might also be struggling to accept themselves.
"The only reason why I did formally address it is just to help youth that are feeling the same way, that are scared to come out — and even adults that are the same way, that are scared to come out — was just to share my story so I could help other people," he said.
According to a previous report from The Blast, the Hulu star told podcast host Jay Shetty that she was "gay and bi" before saying her breakup with her last boyfriend inspired her to act on her attraction to women.
Elsewhere in her interview, Taylor said that she was surprised to learn people in the LGBTQ+ community still experience ******* phobia.
#people #reason #same
22 days ago
DALLAS - Some Republicans are saying they are worried about the cost and inflationary impacts of President Donald Trump's pledge to give American adults a $5,000 dividend if the GOP maintains control of Congress after the midterm election.
While a few Republicans expressed enthusiasm - Sen Bernie Moreno (R-Ohio) said on X he will "get a bill ready" to get the dividend "passed immediately" after the election - a number of them expressed skepticism about Trump's promise.
Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post.
Several lawmakers, including Rep. Monica De La Cruz (R-Texas), who is facing a competitive reelection bid, said Trump's speech was the first "we all heard about" the dividend proposal.
"We're going to see what, actually, [and] how this plays out," said Scott Singer (R-Florida), who also first heard about the dividends during Trump's speech and is running in a swing district. "We'll actually see the specifics, but I believe tax cuts are going to provide the benefits that we need."
#post #expressed #heard
While a few Republicans expressed enthusiasm - Sen Bernie Moreno (R-Ohio) said on X he will "get a bill ready" to get the dividend "passed immediately" after the election - a number of them expressed skepticism about Trump's promise.
Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post.
Several lawmakers, including Rep. Monica De La Cruz (R-Texas), who is facing a competitive reelection bid, said Trump's speech was the first "we all heard about" the dividend proposal.
"We're going to see what, actually, [and] how this plays out," said Scott Singer (R-Florida), who also first heard about the dividends during Trump's speech and is running in a swing district. "We'll actually see the specifics, but I believe tax cuts are going to provide the benefits that we need."
#post #expressed #heard
22 days ago
On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints at week 24 in patients with eosinophilic esophagitis. These benefits were sustained through week 52 across both tested doses, accompanied by a safety profile consistent with its approved indications. While CROSSING highlights their joint R&D success, a closer look at their standalone financial performance reveals distinct growth trajectories.
Both pharmaceutical giants delivered solid Q2 2026 results, but AstraZeneca is showing stronger overall financial momentum. AstraZeneca PLC (NYSE:AZN)'s Q2 revenue increased 6% year over year to $15.38 billion, supported by its Oncology franchise, which grew 18% in H1 to $14.12 billion, and its Rare Disease portfolio, which increased 13%. Core EPS rose 21% to $2.63, beating expectations, while management reaffirmed its full-year 2026 outlook for mid-to-high single-digit revenue growth and low double-digit Core EPS growth.
Amgen Inc. (NASDAQ:AMGN) reported Q2 revenue of $10.1 billion, up 10% year over year, while non-GAAP EPS increased 4% to $6.29. Although its key growth products advanced 26%, mature products faced significant biosimilar pressure, with Prolia revenue declining 32% and XGEVA falling 34%. Amgen nevertheless raised its 2026 revenue guidance midpoint to $39.4 billion.
Overall, AZN holds the financial edge due to stronger EPS growth, broader portfolio momentum, and less exposure to the biosimilar erosion affecting AMGN's mature products.
Amgen's bull case is supported by robust growth in key products, which increased 26%, and $3.5 billion in Q2 free cash flow, providing substantial capital flexibility. Wells Fargo raised its Amgen price target to $435 from $400 on September 4, citing potential upside from HORIZON and pipeline ****** ets such as olpasiran. New Phase III VESALIUS-CV data also showed Repatha reduced the risk of death by 20% in high-risk adults without a prior heart attack or stroke, with heart attack risk reductions emerging as early as six months. However, accelerating biosimilar competition affecting legacy franchises such as Prolia and XGEVA remains a key risk to sustained margin expansion.
#revenue #astrazeneca #increased #products
Both pharmaceutical giants delivered solid Q2 2026 results, but AstraZeneca is showing stronger overall financial momentum. AstraZeneca PLC (NYSE:AZN)'s Q2 revenue increased 6% year over year to $15.38 billion, supported by its Oncology franchise, which grew 18% in H1 to $14.12 billion, and its Rare Disease portfolio, which increased 13%. Core EPS rose 21% to $2.63, beating expectations, while management reaffirmed its full-year 2026 outlook for mid-to-high single-digit revenue growth and low double-digit Core EPS growth.
Amgen Inc. (NASDAQ:AMGN) reported Q2 revenue of $10.1 billion, up 10% year over year, while non-GAAP EPS increased 4% to $6.29. Although its key growth products advanced 26%, mature products faced significant biosimilar pressure, with Prolia revenue declining 32% and XGEVA falling 34%. Amgen nevertheless raised its 2026 revenue guidance midpoint to $39.4 billion.
Overall, AZN holds the financial edge due to stronger EPS growth, broader portfolio momentum, and less exposure to the biosimilar erosion affecting AMGN's mature products.
Amgen's bull case is supported by robust growth in key products, which increased 26%, and $3.5 billion in Q2 free cash flow, providing substantial capital flexibility. Wells Fargo raised its Amgen price target to $435 from $400 on September 4, citing potential upside from HORIZON and pipeline ****** ets such as olpasiran. New Phase III VESALIUS-CV data also showed Repatha reduced the risk of death by 20% in high-risk adults without a prior heart attack or stroke, with heart attack risk reductions emerging as early as six months. However, accelerating biosimilar competition affecting legacy franchises such as Prolia and XGEVA remains a key risk to sustained margin expansion.
#revenue #astrazeneca #increased #products
22 days ago
Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
As a general guideline, if you want multiple credit cards, it's a good idea to wait at least six months between credit card applications. That period gives your credit time to recover from credit inquiries, keeps your average account age healthy, and shows creditors you can manage your debt responsibly.
On average, American adults have 3.7 active cards, according to 2025 data from Experian.
Experts typically recommend waiting at least six months between credit card applications to protect your credit.
Each new credit card application can affect your credit because of hard credit checks and a lower average account age.
#affect #cards
As a general guideline, if you want multiple credit cards, it's a good idea to wait at least six months between credit card applications. That period gives your credit time to recover from credit inquiries, keeps your average account age healthy, and shows creditors you can manage your debt responsibly.
On average, American adults have 3.7 active cards, according to 2025 data from Experian.
Experts typically recommend waiting at least six months between credit card applications to protect your credit.
Each new credit card application can affect your credit because of hard credit checks and a lower average account age.
#affect #cards
22 days ago
"When I was eight or nine I was beating adults at chess and they were raging when they lost, like 'I just lost to a little kid'."
Ethan first became interested in chess when he was six years old after he spotted someone else playing.
Now 13, he plays for Strand Chess Club in east Belfast and has represented Ireland through all his age groups.
Last week he became the youngest Ulster chess champion in history – not just in his age category but across all ages.
"I was really surprised because I've never won any of the big tournaments before, I've always got so close and I managed to win it in the end," Ethan told BBC News NI.
#lost #became #strand #club
Ethan first became interested in chess when he was six years old after he spotted someone else playing.
Now 13, he plays for Strand Chess Club in east Belfast and has represented Ireland through all his age groups.
Last week he became the youngest Ulster chess champion in history – not just in his age category but across all ages.
"I was really surprised because I've never won any of the big tournaments before, I've always got so close and I managed to win it in the end," Ethan told BBC News NI.
#lost #became #strand #club
22 days ago
Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
As a general guideline, if you want multiple credit cards, it's a good idea to wait at least six months between credit card applications. That period gives your credit time to recover from credit inquiries, keeps your average account age healthy, and shows creditors you can manage your debt responsibly.
On average, American adults have 3.7 active cards, according to 2025 data from Experian.
Experts typically recommend waiting at least six months between credit card applications to protect your credit.
Each new credit card application can affect your credit because of hard credit checks and a lower average account age.
#credit #affect #advertiser
As a general guideline, if you want multiple credit cards, it's a good idea to wait at least six months between credit card applications. That period gives your credit time to recover from credit inquiries, keeps your average account age healthy, and shows creditors you can manage your debt responsibly.
On average, American adults have 3.7 active cards, according to 2025 data from Experian.
Experts typically recommend waiting at least six months between credit card applications to protect your credit.
Each new credit card application can affect your credit because of hard credit checks and a lower average account age.
#credit #affect #advertiser
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
25 days ago
Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below.
Ever wondered what it would be like to have seven-figures in your 401(k) plan? Well, for at least 769,000 Americans, that's a reality. That's the number of people with at least $1 million in their 401(k) at the end of June 2026, according to Fidelity data cited by Yahoo Finance (1).
That's a tiny fraction of adults with retirement accounts. If you're in this club, you're extremely lucky. You're also sitting on a relatively large IOU to the tax authorities. At age 73, the Internal Revenue Service (IRS) (2) imposes required minimum distributions (RMDs), which are generally taxed as ordinary income.
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
JPMorgan sees gold hitting $5,000/oz by Q4 — and savvy investors are protecting their wealth with a tax-advantaged Gold IRA. Get your free guide from Priority Gold
#like #wealth #ever
Ever wondered what it would be like to have seven-figures in your 401(k) plan? Well, for at least 769,000 Americans, that's a reality. That's the number of people with at least $1 million in their 401(k) at the end of June 2026, according to Fidelity data cited by Yahoo Finance (1).
That's a tiny fraction of adults with retirement accounts. If you're in this club, you're extremely lucky. You're also sitting on a relatively large IOU to the tax authorities. At age 73, the Internal Revenue Service (IRS) (2) imposes required minimum distributions (RMDs), which are generally taxed as ordinary income.
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
JPMorgan sees gold hitting $5,000/oz by Q4 — and savvy investors are protecting their wealth with a tax-advantaged Gold IRA. Get your free guide from Priority Gold
#like #wealth #ever
25 days ago
A mall chain many consumers around the United States grew up visiting has closed another 25 stores over the last three months.
Earlier this year, we saw a number of mall retailers close locations, despite July 2026 Placer.ai data revealing that foot traffic across all three mall formats grew year over year. As part of my retail coverage for TheStreet, I reported on Vera Bradley cutting its traditional mall footprint by more than 43%, and Fossil Group quietly closing 219 stores over five years.
Most retailers choosing not to renew their mall leases are shifting their strategies. Some are pivoting to open-air shopping centers, which have been outperforming traditional malls for a while, while others are responding to changing consumer preferences by investing more in their online presence.
Founded in 1924, Genesco is a footwear-first company and the engine behind popular brands focused on kids, teens, and young adults. These include Little Burgundy, Journeys, and Schuh.
Genesco has closed another 25 stores across its portfolio, including 17 Journeys Group locations, in the second quarter of fiscal 2027, according to the company's latest earnings release.
#stores #retailers
Earlier this year, we saw a number of mall retailers close locations, despite July 2026 Placer.ai data revealing that foot traffic across all three mall formats grew year over year. As part of my retail coverage for TheStreet, I reported on Vera Bradley cutting its traditional mall footprint by more than 43%, and Fossil Group quietly closing 219 stores over five years.
Most retailers choosing not to renew their mall leases are shifting their strategies. Some are pivoting to open-air shopping centers, which have been outperforming traditional malls for a while, while others are responding to changing consumer preferences by investing more in their online presence.
Founded in 1924, Genesco is a footwear-first company and the engine behind popular brands focused on kids, teens, and young adults. These include Little Burgundy, Journeys, and Schuh.
Genesco has closed another 25 stores across its portfolio, including 17 Journeys Group locations, in the second quarter of fiscal 2027, according to the company's latest earnings release.
#stores #retailers
25 days ago
DBS has introduced two new payment cards, Chromo and TravelLah!, aimed at spending habits and preferences among Gen Z customers in Singapore.
The Singapore-headquartered lender stated that both products are designed to help young adults "maximise rewards" on daily spending and "get more value" when they spend overseas.
DBS launched Chromo on 5 September. It described Chromo as the first credit card in Singapore designed to "automatically adapt" to the spending habits of Gen Z customers.
The card provides bonus cashback on a customer's top two eligible local spending categories each month, removing the need for cardholders to pre-select categories.
DBS Singapore Payments and Unsecured Lending head Chan Sow Han said: "Young adults in their 20s are navigating one of the most dynamic stages of their lives, often marked by shifts in income, interests and financial priorities.
#young #adults
The Singapore-headquartered lender stated that both products are designed to help young adults "maximise rewards" on daily spending and "get more value" when they spend overseas.
DBS launched Chromo on 5 September. It described Chromo as the first credit card in Singapore designed to "automatically adapt" to the spending habits of Gen Z customers.
The card provides bonus cashback on a customer's top two eligible local spending categories each month, removing the need for cardholders to pre-select categories.
DBS Singapore Payments and Unsecured Lending head Chan Sow Han said: "Young adults in their 20s are navigating one of the most dynamic stages of their lives, often marked by shifts in income, interests and financial priorities.
#young #adults
25 days ago
More than 200 older adults were talked into withdrawing their savings and handing it to couriers sent to collect it.
Tarrant County, Texas, prosecutors put the total allegedly fleeced at more than $250 million. A call would come in warning that the victim's money wasn't safe where it was. The instruction was to get it out of the bank and into gold, bitcoin or cash.
And they say the gold rarely stayed gold for long. It moved through shell companies to a refinery in Florida, where gold bars became molten puddles.
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake. Here's what it is and 3 simple steps to fix it ASAP
#jeff
Tarrant County, Texas, prosecutors put the total allegedly fleeced at more than $250 million. A call would come in warning that the victim's money wasn't safe where it was. The instruction was to get it out of the bank and into gold, bitcoin or cash.
And they say the gold rarely stayed gold for long. It moved through shell companies to a refinery in Florida, where gold bars became molten puddles.
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake. Here's what it is and 3 simple steps to fix it ASAP
#jeff
25 days ago
On August 5, Vaxcyte (NASDAQ:PCVX) reported second-quarter results that read less like a snapshot of today and more like a countdown to a verdict. The clinical-stage vaccine maker has no product on the market yet, but its three late-stage trials for its lead pneumococcal candidate are now fully enrolled, with the first major readout due before year-end. Add a net loss that nearly doubled and a boardroom that just brought in two vaccine-industry veterans, and you have a company betting its near-term story on data still to come.
Vaxcyte's three Phase 3 studies of VAX-31, its next-generation pneumococcal conjugate vaccine, have dosed 6,191 adults combined, with roughly 3,500 of them receiving the actual candidate. The largest, OPUS-1, put 4,049 participants through head-to-head comparisons against Prevnar 20 and Capvaxive, the two shots VAX-31 needs to beat to earn a spot in the standard vaccination schedule. Data on safety, tolerability, and immune response from that trial are due in the fourth quarter of 2026, with results from OPUS-2 and OPUS-3 following in the first half of 2027.
A separate Phase 2 study testing VAX-31 in infants, covering both the primary immunization series and a booster dose, is on a similar timeline. In June, Vaxcyte also dosed the first participants in a Phase 1 study of VAX-A1, aimed at preventing disease from Group A Streptococcus, with topline data expected in the second half of 2027. As of June 30, cash and investments stood at $2.5 billion, up from $2.44 billion at the end of 2025, and the board added Dr. Moncef Slaoui, previously chief scientific advisor to Operation Warp Speed and a three-decade GSK veteran, alongside Dr. John Markels, the former president of Merck's global vaccines business.
None of that pipeline progress comes cheap. Vaxcyte's net loss for the quarter ended June 30 was $284.3 million, up from $166.6 million in the same period a year earlier, and the increase shows up on both sides of the ledger. R&D spending rose to $267.9 million from $194.2 million, driven by manufacturing work to prepare for a possible launch and by the cost of running three simultaneous Phase 3 trials at once. G&A expenses climbed too, to $34.9 million from $32 million, largely from adding headcount.
Because Vaxcyte has no approved product generating sales, every one of those dollars comes straight off the balance sheet. The calendar adds pressure of its own: even a clean OPUS-1 readout in the fourth quarter of 2026 still leaves the OPUS-2 and OPUS-3 results, plus a required manufacturing consistency study, sitting in the first half of 2027, pushing any license application and launch well beyond that. The newer VAX-A1 program is earlier still, with its second stage contingent on a safety board signing off on the first.
#phase
Vaxcyte's three Phase 3 studies of VAX-31, its next-generation pneumococcal conjugate vaccine, have dosed 6,191 adults combined, with roughly 3,500 of them receiving the actual candidate. The largest, OPUS-1, put 4,049 participants through head-to-head comparisons against Prevnar 20 and Capvaxive, the two shots VAX-31 needs to beat to earn a spot in the standard vaccination schedule. Data on safety, tolerability, and immune response from that trial are due in the fourth quarter of 2026, with results from OPUS-2 and OPUS-3 following in the first half of 2027.
A separate Phase 2 study testing VAX-31 in infants, covering both the primary immunization series and a booster dose, is on a similar timeline. In June, Vaxcyte also dosed the first participants in a Phase 1 study of VAX-A1, aimed at preventing disease from Group A Streptococcus, with topline data expected in the second half of 2027. As of June 30, cash and investments stood at $2.5 billion, up from $2.44 billion at the end of 2025, and the board added Dr. Moncef Slaoui, previously chief scientific advisor to Operation Warp Speed and a three-decade GSK veteran, alongside Dr. John Markels, the former president of Merck's global vaccines business.
None of that pipeline progress comes cheap. Vaxcyte's net loss for the quarter ended June 30 was $284.3 million, up from $166.6 million in the same period a year earlier, and the increase shows up on both sides of the ledger. R&D spending rose to $267.9 million from $194.2 million, driven by manufacturing work to prepare for a possible launch and by the cost of running three simultaneous Phase 3 trials at once. G&A expenses climbed too, to $34.9 million from $32 million, largely from adding headcount.
Because Vaxcyte has no approved product generating sales, every one of those dollars comes straight off the balance sheet. The calendar adds pressure of its own: even a clean OPUS-1 readout in the fourth quarter of 2026 still leaves the OPUS-2 and OPUS-3 results, plus a required manufacturing consistency study, sitting in the first half of 2027, pushing any license application and launch well beyond that. The newer VAX-A1 program is earlier still, with its second stage contingent on a safety board signing off on the first.
#phase
25 days ago
Florida Attorney General James Uthmeier says his office will seek the death penalty for the two adults who allegedly confined four children to the cab of a tractor-trailer, some for more than six years, and ***** ually abused them.
Keisha Monique Epps, 51, and Tamra Marshon Stewart, 37, have been charged with ***** ual battery, molestation and neglect of two girls and two boys — two 5-year-olds, a 6-year-old and a 9-year-old, Uthmeier said.
Epps and Stewart, who has been identified as her fiancé, had been living in the cab with the children. Epps worked as a truck driver, frequenting a route between Miami and Atlanta, according to court documents.
Florida Couple Allegedly Held Four Children In Tractor-trailer Cab For Nearly Seven Years
Keisha Epps and Tamra Marshon Stewart were arrested Aug. 6 and remain jailed as they await trial on child neglect charges.
#keisha #allegedly
Keisha Monique Epps, 51, and Tamra Marshon Stewart, 37, have been charged with ***** ual battery, molestation and neglect of two girls and two boys — two 5-year-olds, a 6-year-old and a 9-year-old, Uthmeier said.
Epps and Stewart, who has been identified as her fiancé, had been living in the cab with the children. Epps worked as a truck driver, frequenting a route between Miami and Atlanta, according to court documents.
Florida Couple Allegedly Held Four Children In Tractor-trailer Cab For Nearly Seven Years
Keisha Epps and Tamra Marshon Stewart were arrested Aug. 6 and remain jailed as they await trial on child neglect charges.
#keisha #allegedly
26 days ago
Prince William and Princess Kate's children might not have met up with Prince Harry and Meghan Markle's kids during their recent trip to the U.K., but now that the Sussexes have officially moved back to England, that could soon change.
"Kate's telling [William] that the children deserve the opportunity to get to know their cousins," a source tells Closer. "It was one thing when Archie and Lilibet were on another continent. It was easy to make excuses then. But now, they will be so close."
On Tuesday, August 26, the BBC reported that Harry, 41, and Meghan, 45, and their children, Prince Archie, 7, and Princess Lilibet, 5, touched down in Birmingham, England via private jet.
The Wales' ongoing estrangement from the Sussexes "is going to be very difficult to explain and justify to" Prince George, 13, Princess Charlotte, 11, and Prince Louis, 8, the source notes. "Especially when William and Kate have always emphasized how important it is for them to get along and now here is this example of the adults not being able to make peace."
Francis Dias/NEWSPIX INTERNATIONAL / MEGA
#prince #lilibet
"Kate's telling [William] that the children deserve the opportunity to get to know their cousins," a source tells Closer. "It was one thing when Archie and Lilibet were on another continent. It was easy to make excuses then. But now, they will be so close."
On Tuesday, August 26, the BBC reported that Harry, 41, and Meghan, 45, and their children, Prince Archie, 7, and Princess Lilibet, 5, touched down in Birmingham, England via private jet.
The Wales' ongoing estrangement from the Sussexes "is going to be very difficult to explain and justify to" Prince George, 13, Princess Charlotte, 11, and Prince Louis, 8, the source notes. "Especially when William and Kate have always emphasized how important it is for them to get along and now here is this example of the adults not being able to make peace."
Francis Dias/NEWSPIX INTERNATIONAL / MEGA
#prince #lilibet
27 days ago
On August 5, Vaxcyte (NASDAQ:PCVX) reported second-quarter results that read less like a snapshot of today and more like a countdown to a verdict. The clinical-stage vaccine maker has no product on the market yet, but its three late-stage trials for its lead pneumococcal candidate are now fully enrolled, with the first major readout due before year-end. Add a net loss that nearly doubled and a boardroom that just brought in two vaccine-industry veterans, and you have a company betting its near-term story on data still to come.
Vaxcyte's three Phase 3 studies of VAX-31, its next-generation pneumococcal conjugate vaccine, have dosed 6,191 adults combined, with roughly 3,500 of them receiving the actual candidate. The largest, OPUS-1, put 4,049 participants through head-to-head comparisons against Prevnar 20 and Capvaxive, the two shots VAX-31 needs to beat to earn a spot in the standard vaccination schedule. Data on safety, tolerability, and immune response from that trial are due in the fourth quarter of 2026, with results from OPUS-2 and OPUS-3 following in the first half of 2027.
A separate Phase 2 study testing VAX-31 in infants, covering both the primary immunization series and a booster dose, is on a similar timeline. In June, Vaxcyte also dosed the first participants in a Phase 1 study of VAX-A1, aimed at preventing disease from Group A Streptococcus, with topline data expected in the second half of 2027. As of June 30, cash and investments stood at $2.5 billion, up from $2.44 billion at the end of 2025, and the board added Dr. Moncef Slaoui, previously chief scientific advisor to Operation Warp Speed and a three-decade GSK veteran, alongside Dr. John Markels, the former president of Merck's global vaccines business.
None of that pipeline progress comes cheap. Vaxcyte's net loss for the quarter ended June 30 was $284.3 million, up from $166.6 million in the same period a year earlier, and the increase shows up on both sides of the ledger. R&D spending rose to $267.9 million from $194.2 million, driven by manufacturing work to prepare for a possible launch and by the cost of running three simultaneous Phase 3 trials at once. G&A expenses climbed too, to $34.9 million from $32 million, largely from adding headcount.
Because Vaxcyte has no approved product generating sales, every one of those dollars comes straight off the balance sheet. The calendar adds pressure of its own: even a clean OPUS-1 readout in the fourth quarter of 2026 still leaves the OPUS-2 and OPUS-3 results, plus a required manufacturing consistency study, sitting in the first half of 2027, pushing any license application and launch well beyond that. The newer VAX-A1 program is earlier still, with its second stage contingent on a safety board signing off on the first.
#opus #data
Vaxcyte's three Phase 3 studies of VAX-31, its next-generation pneumococcal conjugate vaccine, have dosed 6,191 adults combined, with roughly 3,500 of them receiving the actual candidate. The largest, OPUS-1, put 4,049 participants through head-to-head comparisons against Prevnar 20 and Capvaxive, the two shots VAX-31 needs to beat to earn a spot in the standard vaccination schedule. Data on safety, tolerability, and immune response from that trial are due in the fourth quarter of 2026, with results from OPUS-2 and OPUS-3 following in the first half of 2027.
A separate Phase 2 study testing VAX-31 in infants, covering both the primary immunization series and a booster dose, is on a similar timeline. In June, Vaxcyte also dosed the first participants in a Phase 1 study of VAX-A1, aimed at preventing disease from Group A Streptococcus, with topline data expected in the second half of 2027. As of June 30, cash and investments stood at $2.5 billion, up from $2.44 billion at the end of 2025, and the board added Dr. Moncef Slaoui, previously chief scientific advisor to Operation Warp Speed and a three-decade GSK veteran, alongside Dr. John Markels, the former president of Merck's global vaccines business.
None of that pipeline progress comes cheap. Vaxcyte's net loss for the quarter ended June 30 was $284.3 million, up from $166.6 million in the same period a year earlier, and the increase shows up on both sides of the ledger. R&D spending rose to $267.9 million from $194.2 million, driven by manufacturing work to prepare for a possible launch and by the cost of running three simultaneous Phase 3 trials at once. G&A expenses climbed too, to $34.9 million from $32 million, largely from adding headcount.
Because Vaxcyte has no approved product generating sales, every one of those dollars comes straight off the balance sheet. The calendar adds pressure of its own: even a clean OPUS-1 readout in the fourth quarter of 2026 still leaves the OPUS-2 and OPUS-3 results, plus a required manufacturing consistency study, sitting in the first half of 2027, pushing any license application and launch well beyond that. The newer VAX-A1 program is earlier still, with its second stage contingent on a safety board signing off on the first.
#opus #data
27 days ago
Over the past five years, Eli Lilly (NYSE: LLY) stock managed a total return of 376%. If the stock managed a repeat over the next five years, share prices would top $5,500. Much of its current performance boost is thanks to enthusiasm over its GLP-1 offerings.
Are the same factors that led to the healthcare company's sharp rise likely to recur? The simple answer is no. While its metabolic GLP-1 weight-loss therapies helped spike revenue, it's not likely to happen again. Still, there are reasons to believe the pharmaceutical stock could double in value over the next five years, making a $5,000 investment in Eli Lilly stock worth more than $10,000 in five years. Here's why.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Eli Lilly, through tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, is still a leader in the GLP-1 **** e. Tirzepatide is showing to be an incredibly versatile incretin-based peptide drug.
Excess weight is tied to many health problems, and tirzepatide could expand to adjacent indications. It has already been approved to treat obstructive sleep apnea, and on Aug. 28, the Food and Drug Administration (FDA) approved Mounjaro to lower the risk of major adverse cardiovascular (CV) events, including cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk.
#Stock #signal #weight #total
Are the same factors that led to the healthcare company's sharp rise likely to recur? The simple answer is no. While its metabolic GLP-1 weight-loss therapies helped spike revenue, it's not likely to happen again. Still, there are reasons to believe the pharmaceutical stock could double in value over the next five years, making a $5,000 investment in Eli Lilly stock worth more than $10,000 in five years. Here's why.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Eli Lilly, through tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, is still a leader in the GLP-1 **** e. Tirzepatide is showing to be an incredibly versatile incretin-based peptide drug.
Excess weight is tied to many health problems, and tirzepatide could expand to adjacent indications. It has already been approved to treat obstructive sleep apnea, and on Aug. 28, the Food and Drug Administration (FDA) approved Mounjaro to lower the risk of major adverse cardiovascular (CV) events, including cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk.
#Stock #signal #weight #total
28 days ago
Gilead Sciences (NASDAQ: GILD) has no major concerns about its HIV franchise until the next decade. That hasn't kept the pharmaceutical company from preparing for the loss of exclusivity for its legacy HIV therapies. Gilead has spent heavily on its pipeline, and that's paying off.
The company has received three Food and Drug (FDA) approvals over the past four months, and not coincidentally, its shares are up more than 21% so far this year, nearly doubling the S&P 500 index's rise. The most recent approval was on Aug. 27 for Bixlenvo as a daily pill to treat virologically suppressed adults with HIV.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Prior to that, on June 24, Trodelvy received two new approvals to treat triple-negative breast cancer. On May 22, the FDA granted Hepcludex accelerated approval to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis.
Despite the stock's rise and all the good news on the pipeline front, Gilead may be underrated. There are three reasons why I feel that is the case.
#gilead #NVIDIA #three
The company has received three Food and Drug (FDA) approvals over the past four months, and not coincidentally, its shares are up more than 21% so far this year, nearly doubling the S&P 500 index's rise. The most recent approval was on Aug. 27 for Bixlenvo as a daily pill to treat virologically suppressed adults with HIV.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Prior to that, on June 24, Trodelvy received two new approvals to treat triple-negative breast cancer. On May 22, the FDA granted Hepcludex accelerated approval to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis.
Despite the stock's rise and all the good news on the pipeline front, Gilead may be underrated. There are three reasons why I feel that is the case.
#gilead #NVIDIA #three
28 days ago
Starting statin therapy shortly after a type 2 diabetes diagnosis may not only protect the heart — it may also be linked to a lower dementia risk.
A large study presented at the European Society of Cardiology Congress in Munich on Aug. 30 found that adults who began taking a statin within one year of their type 2 diabetes diagnosis had a 15% lower relative risk of developing dementia over 10 years compared to those who did not take the medication within five years.
Even for those who delayed starting a statin for one to five years, there was still a 10% lower relative risk, according to the findings, which were published in The Lancet Regional Health – Europe.
3 Things To Avoid In Middle Age Could Mean 13 More Years Without Dementia, Study Finds
A statin is a prescription medication that lowers "bad" LDL cholesterol and helps reduce the risk of heart attack and stroke.
#risk #lower #study #diagnosis
A large study presented at the European Society of Cardiology Congress in Munich on Aug. 30 found that adults who began taking a statin within one year of their type 2 diabetes diagnosis had a 15% lower relative risk of developing dementia over 10 years compared to those who did not take the medication within five years.
Even for those who delayed starting a statin for one to five years, there was still a 10% lower relative risk, according to the findings, which were published in The Lancet Regional Health – Europe.
3 Things To Avoid In Middle Age Could Mean 13 More Years Without Dementia, Study Finds
A statin is a prescription medication that lowers "bad" LDL cholesterol and helps reduce the risk of heart attack and stroke.
#risk #lower #study #diagnosis
28 days ago
The keto diet may have surprising benefits for liver health, a new study suggests.
The research, published in the journal Cell Metabolism, studied 42 adults who had obesity, prediabetes and excess liver fat.
In a randomized clinical trial, the participants were ***** igned to three weight-loss diets – a low-carb ketogenic diet, a Mediterranean diet and a low-fat, mostly plant-based diet.
Secret To Weight Loss May Be Hiding In Your Gut, New Study Suggests
The keto diet's calories consisted of about 4% carbohydrates and 73% fat, according to the study. The Mediterranean diet provided about 50% of calories from carbohydrates and 35% from fat, while the low-fat diet provided about 70% of calories from carbohydrates and 15% from fat.
#liver
The research, published in the journal Cell Metabolism, studied 42 adults who had obesity, prediabetes and excess liver fat.
In a randomized clinical trial, the participants were ***** igned to three weight-loss diets – a low-carb ketogenic diet, a Mediterranean diet and a low-fat, mostly plant-based diet.
Secret To Weight Loss May Be Hiding In Your Gut, New Study Suggests
The keto diet's calories consisted of about 4% carbohydrates and 73% fat, according to the study. The Mediterranean diet provided about 50% of calories from carbohydrates and 35% from fat, while the low-fat diet provided about 70% of calories from carbohydrates and 15% from fat.
#liver
